Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.

被引：5
|
作者：
Drakaki, Alexandra
Kirby, Conor J.
Van der Heijden, Michiel Simon
Petrylak, Daniel Peter
Powles, Thomas
Chi, Kim N.
Flechon, Aude
Necchi, Andrea
Geczi, Lajos
Lee, Jae-Lyun
Gakis, Georgios
Bracarda, Sergio
Chowdhury, Simon
Lin, Chia-Chi
Keizman, Daniel
Vaishampayan, Ulka N.
Liepa, Astra M.
Zimmermann, Annamaria
Bell-McGuinn, Katherine M.
Castellano, Daniel E.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Marian Univ Coll Osteopath Med Eli Lilly & Co, Indianapolis, IN USA
[3] Antoni Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands
[4] Yale Sch Med, New Haven, CT USA
[5] Barts Hlth NHS Trust St Bartholomews Hosp, London, England
[6] BC Canc Agcy, Vancouver, BC, Canada
[7] Ctr Leon Berard, Lyon, France
[8] Fondazione IRCCS Ist Nazl Tumori, Milan, Italy
[9] Natl Inst Oncol, Budapest, Hungary
[10] Univ Ulsan Coll Med Asan Med Ctr, Seoul, South Korea
[11] Univ Hosp Wurzburg, Wurzburg, Denmark
[12] San Donato Hosp, Ist Toscano Tumori, Arezzo, Italy
[13] Sarah Cannon Res Inst, London, England
[14] Natl Taiwan Univ Hosp, Taipei, Taiwan
[15] Meir Med Ctr, Kefar Sava, Israel
[16] Karmanos Canc Ctr, Detroit, MI USA
[17] Eli Lilly & Co, Indianapolis, IN USA
[18] Hosp Octubre 12, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
434
引用
收藏
页数：1
相关论文
共 20 条
  • [1] A subgroup analysis of the East Asia population in RANGE: A randomized phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma (UC)
    Matsubara, Nobuaki
    Petrylak, Daniel Peter
    Nishiyama, Hiroyuki
    Su, Wen-Pin
    Lee, Jae-Lyun
    Li, Jian-Ri
    Walgren, Richard A.
    Hamid, Oday
    Zimmermann, Annamaria
    Bell-McGuinn, Katherine M.
    Gao, Ling
    Homma, Gosuke
    Yana, Ikuo
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial
    Drakaki, Alexandra
    Kirby, Conor J.
    Van der Heijden, Michiel S.
    Petrylak, Daniel P.
    Powles, Thomas
    Chi, Kim N.
    Flechon, Aude
    Necchi, Andrea
    Geczi, Lajos
    Lee, Jae-Lyun
    Gakis, Georgios
    Bracarda, Sergio
    Chowdhury, Simon
    Lin, Chia-Chi
    Keizman, Daniel
    Vaishampayan, Ulka N.
    Zimmermann, Annamaria H.
    Bell-McGuinn, Katherine
    Castellano, Daniel
    BLADDER CANCER, 2020, 6 (01) : 43 - 52
  • [3] RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma
    Petrylak, D. P.
    Chi, K. N.
    Drakaki, A.
    Sternberg, C. N.
    de Wit, R.
    Nishiyama, H.
    Yu, E. Y.
    Castellano, D.
    Hussain, S.
    Percent, I. J.
    Flechon, A.
    Bamias, A.
    Van der Heijden, M. S.
    Matsubara, N.
    Alekseev, B.
    Walgren, R. A.
    Hamid, O.
    Zimmermann, A. H.
    Bell-Mcguinn, K. M.
    Powles, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
    Andrea Necchi
    Hiroyuki Nishiyama
    Nobuaki Matsubara
    Jae-Lyun Lee
    Daniel P. Petrylak
    Ronald de Wit
    Alexandra Drakaki
    Astra M. Liepa
    Huzhang Mao
    Katherine Bell-McGuinn
    Thomas Powles
    BMC Urology, 20
  • [5] Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)
    Necchi, Andrea
    Nishiyama, Hiroyuki
    Matsubara, Nobuaki
    Lee, Jae-Lyun
    Petrylak, Daniel P.
    de Wit, Ronald
    Drakaki, Alexandra
    Liepa, Astra M.
    Mao, Huzhang
    Bell-McGuinn, Katherine
    Powles, Thomas
    BMC UROLOGY, 2020, 20 (01)
  • [6] Afatinib activity in platinum-refractory metastatic urothelial carcinoma (UC) patients with ErbB alterations: Results of a phase II trial.
    Choudhury, Noura
    Campanile, Alexa
    Antic, Tatjana
    Wade, James Lloyd
    Stadler, Walter Michael
    Nakamura, Yusuke
    O'Donnell, Peter H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [7] RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results
    Petrylak, D. P.
    Sternberg, C. N.
    Drakaki, A.
    de Wit, R.
    Nishiyama, H.
    Necchi, A.
    Castellano, D.
    Bamias, A.
    Chi, K. N.
    van der Heijden, M. S.
    Matsubara, N.
    Hussain, S.
    Flechon, A.
    Alekseev, B. Y.
    Yu, E. Y.
    Walgren, R. A.
    Russo, F.
    Zimmermann, A. H.
    Bell-Mcguinn, K. M.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC).
    Necchi, Andrea
    Nishiyama, Hiroyuki
    Matsubara, Nobuaki
    Lee, Jae-Lyun
    Petrylak, Daniel Peter
    De Wit, Ronald
    Drakaki, Alexandra
    Liepa, Astra M.
    Zimmermann, Annamaria
    Bell-McGuinn, Katherine M.
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [9] Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial.
    Choudhury, Noura
    Campanile, Alexa
    Wade, James Lloyd
    Antic, Tatjana
    Stadler, Walter Michael
    Nakamura, Yusuke
    O'Donnell, Peter H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [10] Association of HER2 and ErbB3 molecular alterations with afatinib sensitivity in platinum-refractory metastatic urothelial carcinoma (UC) in a phase II trial.
    Choudhury, Noura
    Campanile, Alexa
    Wade, James Lloyd
    Antic, Tatjana
    Stadler, Walter Michael
    Nakamura, Yusuke
    O'Donnell, Peter H.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12